Key Highlights
- First-half Revenue rose 72% to approximately $8.3m, and 46% above the second half of 2025.
- Full-year guidance was raised to at least $14.8m, against prior market expectations of $13.3m.
- Gross Margin held at around 36%, in line with the full year 2025.
- Net cash and investments fell to $4.4m at the end of 2025 from $6.7m a year earlier.
Itaconix plc (LSE:ITX) has spent most of its life on London's junior market as a small, loss-making speciality chemicals developer with a good story and thin revenues. That description is becoming outdated. On 17 July 2026 the company said first-half revenue had jumped 72% to a record $8.3m, and it raised full-year revenue guidance to at least $14.8m, above the $13.3m the market had expected.
The next test comes quickly: interim results are due on 8 September 2026. The key question is whether the plant-based polymer maker can convert record sales into its first year of positive adjusted EBITDA, and whether plastic-free detergent tablets, paints and crop-nutrition products can broaden a Business that still leans on a handful of dishwashing-detergent customers.
Trading update: record first half and guidance raised
In the 17 July 2026 trading update, revenue for the six months to 30 June 2026 was approximately $8.3m, up 72% from $4.8m in the first half of 2025 and 46% above the $5.7m recorded in the second half of 2025. Gross margin held at around 36%, in line with full-year 2025.
On the strength of that performance, the board said it now expects revenue for the year to 31 December 2026 of at least $14.8m, against prior market expectations of $13.3m, and a small positive EBITDA result. Growth came from Performance Ingredients, serving dish-detergent makers in EMEA and North America, and from SPARX Formulated Solutions. New wins included a unit-dose dish-detergent customer in EMEA and a unit-dose laundry-detergent customer in North America, alongside strong reorders from existing accounts. "We are pleased with progress across the business and at this stage of the financial year," the company said.
Two smaller announcements preceded it. On 8 July 2026 Itaconix extended its collaboration with tableting specialist Bonals Technologies to December 2028, and on 14 July 2026 it announced its first Supply agreement for an 8-gram, plastic-free dish-detergent tablet with an unnamed North American brand, due at retail by the end of 2026. Chief executive John R. Shaw said the company's ingredients were "leading a new generation of plastic-free solid unit-dose detergents".
What Itaconix does
Itaconix develops and manufactures speciality polymers derived from itaconic acid, a plant-based building block, sold as ingredients for everyday consumer and industrial products. Its core chemistry provides scale inhibition in dishwashing detergents (the TSI range) and odour neutralisation in laundry care (the ZINADOR range, distributed globally by Croda under an agreement extended in July 2025 to at least 2030).
Itaconix Performance Ingredients generated $7.6m, or 73%, of 2025 revenue; SPARX Formulated Solutions, which supplies finished detergent formulations and now tablets, contributed $2.9m, or 27%; BIO*Asterix speciality monomers for paints remain pre-revenue, and BioVail plant-nutrition ingredients are in field trials. North America accounted for $6.5m (62%) of 2025 revenue and EMEA $4.0m (38%). The company is headquartered in London with one production Facility in North America and warehouses in both regions. Three customers represented 48% of 2025 revenue.
Full-year 2025 results: revenue up 61%, losses narrowing
Preliminary results for the year to 31 December 2025, published on 24 March 2026, showed revenue of $10.5m, up 61% from $6.5m in 2024. Gross Profit rose 61% to $3.6m at an unchanged 34.7% margin. The adjusted EBITDA loss narrowed to $0.6m from $1.8m, the operating loss to $1.0m from $2.2m, and the loss before tax to $1.4m from $2.0m. Loss per share was 10.2 cents against 15.0 cents. Operating cash outflow fell to $1.2m from $2.8m, with Capital Expenditure of $0.6m.
Year-end cash was $2.4m, with a further $2.0m in investments, giving net cash and investments of $4.4m, down from $6.7m a year earlier; no borrowings were disclosed and no Dividend was paid. The directors concluded that the group had adequate Liquidity for at least 12 months from approval of the accounts on 23 March 2026, dependent on continued customer Demand and cost management. Market expectations for 2026 at that point were revenue of $13.3m, adjusted EBITDA of $0.3m and net cash of $3m. Mr Shaw called the $10.5m revenue figure an "important milestone" towards a "large, highly profitable, capital efficient specialty" business.
What could drive the stock next?
The immediate catalyst is the interim results on 8 September 2026, followed by an investor presentation on 9 September, which will reveal whether the 72% revenue increase produced a first-half adjusted EBITDA profit and how much cash growth consumed.
Beyond that, further Brand agreements or contract-manufacturing installations under the Bonals Partnership would show that SPARX tablets can scale beyond pilot capacity. Management's 2026 priorities include expanding European scale-inhibitor adoption, which grew 104% in 2025, and rebuilding North American dishwashing revenues, where eight of 17 customer formulations were in production at the year end. Longer-dated Options include production-ready BIO*Asterix paint formulations targeted for the second half of 2027, results from the BioVail crop trials announced in June 2026, and feasibility work on a possible production facility outside the United States by 2031.
Risks investors should watch
Itaconix remains a very small company with a concentrated customer base. With three customers accounting for almost half of 2025 revenue, a reformulation decision by a single large detergent brand could reverse the growth trajectory quickly. Its polymers also compete with established alternatives from much larger chemical suppliers.
Financially, the group is still loss-making before tax and has funded growth from its own balance sheet, with net cash and investments falling from $6.7m to $4.4m during 2025. Faster growth absorbs working capital, and any plant outside the US would need funding not yet identified, so shareholders should be alert to the possibility of a share issue and the dilution it would imply for a company with only 13.5m shares in issue.
Operating a single North American plant while selling into Europe exposes the group to trade policy; it flagged modest Tariff effects in 2025, mitigated by pricing and currency moves. It reports in US dollars, so sterling-based investors carry currency risk, and tablets, paints and agriculture remain early-stage with no guarantee of reaching commercial scale.
Outlook
Itaconix (LSE:ITX) enters its September results with momentum: consecutive record halves, guidance raised above market expectations, and a stated path to positive adjusted EBITDA in 2026. The interim statement will show whether profitability and cash generation are keeping pace with sales, which is the crux of the debate for a business that has historically consumed cash.
Investors should look for the first-half adjusted EBITDA figure, period-end cash and investments, reorder rates from customers won in early 2026, and any update on the plastic-free tablet launch. Sustained delivery would strengthen the case that Itaconix is moving from niche technology developer to self-funding speciality ingredients supplier; a stumble on cash or customer concentration would remind the market how narrow its base still is.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...